Mphoma; PFS, progression-free survival.Survival probabilityLenalidomide Handle 0 5 ten 15 20 25 30 35 40 45Months From randomizationNumber at danger Lenalidomide Manage 73 30 29 9 22 3 13 1 9 1 9 1 7 1 five 1 three 1 two 02017 The Authors. British Journal of Haematology published by John Wiley Sons Ltd. British Journal of Haematology, 2018, 180, 224L. Arcaini et al(E)1 0 0High tumour burden at baselineMedian PFS, months (95 CI) HR (95 CI) Log-rank P worth Lenalidomide Handle 7 (31) 3 (two) 0 (0) 0Survival probability0 0 0 0 0 0 0 0 0 5 10 15 20 25 Manage 30 35 40 45 50 55 60 65 70 LenalidomideMonths from randomizationNumber at risk Lenalidomide Control 81 28 41 7 30 4 21 1 17 1 16 1 13 0 11 7 five four 3 two 1 1(F)1 0 0Bulky illness at baselineMedian PFS, months (95 CI) HR (95 CI) Log-rank P value Lenalidomide Manage 5 (21) 2 (12) 0 (0) 0Survival probability0 0 0 0 0 0 0 0 0 5 10 Handle 15 20 25 30 35 40 45 50 LenalidomideMonths from randomizationNumber at danger Lenalidomide Control 37 13 16 2 12 2 8 0 6 six four 4 1 1(G)1 0 0Refractory patientsMedian PFS, months (95 CI) HR (95 CI) Log-rank P value Lenalidomide Control 6 (33) 1 (1) 0 (0) 0Survival probability0 0 0 0 0 0 0 0 0 5 Manage 10 15 20 25 30 35 40 45 50 55 60 65 LenalidomideMonths from randomizationNumber at danger Lenalidomide Manage 70 25 36 four 27 0 20 18 16 14 12 10 6 six 5 4 two 1Fig 1. Cotinued.(P = 006) and in individuals with each standard (P = 026) and moderate renal function (P = 019). We also evaluated subgroups to examine the prospective effect of prior therapy on PFS outcomes. As shown in Fig 2C, lenalidomide drastically improved PFS compared with IC in patients who were three years from MCLdiagnosis (P = 002); had more prior systemic antilymphoma therapies (P = 002 for two; P = 020 for 3); have been refractory to their last therapy (P 001); had 1 prior relapses (P = 007 for 1, P = 007 for two, P = 006 for 3); no matter time from final prior therapy (P = 042 for 6 months, and P = 033 for2017 The Authors.Ginkgolide A Technical Information British Journal of Haematology published by John Wiley Sons Ltd.Veratramine Formula British Journal of Haematology, 2018, 180, 224MCL-002 Subgroup Evaluation of Lenalidomide versus IC in MCL(A)Subgroup Low MIPI score at Intermeddiagnosis High Low MIPI score at Intermedbaseline Higher Age ECOG PS 65 years 65 years 0-1 two Low LDH Regular Higher 6 WBC (x109/l) 6-10 10-15PFS HR (95 CI)Individuals, n/N Len 41/61 37/51 36/40 28/42 46/66 52/60 41/55 86/115 107/142 20/27 0/2 67/94 59/73 55/79 42/56 15/19 14/15 IC 27/35 17/22 12/14 15/21 27/37 23/25 21/27 45/57 55/73 11/11 2/2 35/51 28/30 37/46 20/27 5/7 4/Median PFS, months Len 7 eight 5 16 12 3 five 10 eight 9 NA 12 three 8 11 eight two IC five six 2 five six 2 6 4 5 1 four 7 two 4 7 8 three Log rank P 035 055 049 059 033 037 037 001 025 019 057 049 016 011 085 004 02 three 4 HR (95 CI)(B)Subgroup Male Sex Female MCL stage I/II at diagnosis III/IV Higher Tumour burden Low Yes Bulky illness No Negative Bone Indetermmarrow Optimistic Normal Renal function Moderate0PFS HR (95 CI)Individuals, n/N Len IC 95/123 49/63 32/47 17/21 10/13 3/3 114/153 61/79 62/81 23/28 57/78 40/50 28/37 11/13 91/122 52/65 22/27 11/11 4/4 3/3 16/21 11/13 98/134 47/63 29/34 19/Median PFS, months Len IC 7 five 11 three six 2 eight six 7 3 13 six five 2 11 5 11 three 2 4 5 7 eight five eight 5Log rank P 055 035 098 014 007 018 068 004 006 023 043 026 02 three 4 HR (95 CI)Fig 2.PMID:23724934 Forest plots of remedy effects on median PFS by subgroups in line with MIPI-based characteristics (A), other patient traits (B), and prior treatment history (C). Enhanced PFS towards the left of the vertical line (i.e.
